DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report 
BB Biotech AG publishes its interim report 
23-Apr-2021 / 07:00 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Media Release, April 23, 2021 
BB Biotech AG publishes its interim report 
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2021, which covers the results of 
its business activities for the first three months of 2021. 
Based on the consolidated accounts of BB Biotech AG, net profit for the period ended March 31, 2021 amounted to CHF 221 
mn (loss of CHF 758 mn in the same period 2020). For an investment company, the results reflect the share price 
development of the companies held in the portfolio. 
The interim report as at March 31, 2021 is available under report.bbbiotech.ch/Q121 or www.bbbiotech.com. 
For further information: 
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland 
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch 
www.bbbiotech.com 
Company profile 
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in 
Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are 
mainly located in the US and Western Europe. 
BB Biotech AG is one of the leading investors in this sector. BB Biotech AG builds on the long-standing experience of 
its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of 
Bellevue Asset Management AG when making its investment decisions. 
=---------------------------------------------------------------------------------------------------------------------- 
23-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
              Switzerland 
Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1187763 
 
End of Announcement  DGAP News Service 
=------------

1187763 23-Apr-2021 CET/CEST


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1187763&application_name=news

(END) Dow Jones Newswires

April 23, 2021 01:03 ET (05:03 GMT)